title: Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
abstract: BACKGROUND
  There is growing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of solid tumors. Colorectal cancer results from the cumulative effect of sequential genetic alterations, leading to the expression of tumor associated antigens possibly inducing a cellular anti-tumor immune response. It is well recognized that cytotoxic lymphocytes constitute one of the most important effector mechanisms of anti-tumor-immunity. However, their potential prognostic influence in colorectal cancer remains controversial. Aim of the study was to examine infiltration of CD3+ and CD8+ lymphocytes in colorectal cancer and their prognostic potential.Two-hundred-fifteen colorectal cancer cases, previously analyzed for microsatellite instability (MSI), were selected for immunohistochemical detection of CD3+, CD8+ infiltration and the expression of granzyme B. Prognostic relevance was assessed by survival analysis.
  
  
  RESULTS
  Strong correlations were found between the infiltration of lymphocytes and several clinicopathological variables. Survival analysis revealed that intra-epithelial infiltration of CD3+ and CD8+ T lymphocytes and stromal infiltration of CD3+ lymphocytes had a major impact on the patients' overall survival in the univariate analysis, however independent of their association with MSI-status. In addition, it was also demonstrated that there was an important disease specific survival advantage for patients with microsatellite stable (MSS) tumors containing intraepithelial CD8+ tumor infiltrating lymphocytes. When samples were analyzed for colon cancer and rectal cancer separately, the results of the overall population were confirmed in colon cancer only. When entered into a multiple Cox regression analysis adjusting for other possible important confounding factors, the strong impact of lymphocyte infiltration on overall survival was not maintained. Only early stage and young age (borderline significant for overall population only) were associated with a better overall survival (early disease with disease-free survival also).
  
  
  CONCLUSIONS
  In conclusion our results suggest a role for infiltrating CD3+ and CD8+ T lymphocytes in colorectal cancer whereby tumor infiltration could reflect a general principle of antitumor immunity, irrespective of the MSI-status.
authors.affiliation: Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp (UA/UZA), Wilrijk, Belgium. vanessa.deschoolmeester@ua.ac.be
authors.forename: Vanessa
authors.initials: V
authors.lastname: Deschoolmeester
authors.forename: Marc
authors.initials: M
authors.lastname: Baay
authors.forename: Eric
authors.initials: E
authors.lastname: Van Marck
authors.forename: Joost
authors.initials: J
authors.lastname: Weyler
authors.forename: Peter
authors.initials: P
authors.lastname: Vermeulen
authors.forename: Filip
authors.initials: F
authors.lastname: Lardon
authors.forename: Jan B
authors.initials: JB
authors.lastname: Vermorken
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged
chemical_list: D014408:Biomarkers, Tumor
references.citation: Br J Cancer. 2004 Nov 1;91(9):1711-7
references.pmid: 15494715
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: Lancet. 1999 Jan 30;353(9150):345-50
references.pmid: 9950438
references.citation: Eur J Cancer. 2007 Feb;43(3):624-31
references.pmid: 17223543
references.citation: Int J Cancer. 2006 Apr 1;118(7):1721-7
references.pmid: 16231316
references.citation: Am J Pathol. 1999 Jun;154(6):1805-13
references.pmid: 10362805
references.citation: Recent Results Cancer Res. 2005;165:260-7
references.pmid: 15865042
references.citation: Cancer. 2001 Jun 15;91(12):2417-22
references.pmid: 11413533
references.citation: Cancer Immun. 2007 Mar 28;7:7
references.pmid: 17388261
references.citation: Cancer Immunol Immunother. 2002 Jul;51(5):235-47
references.pmid: 12070710
references.citation: J Clin Oncol. 2005 Jan 20;23(3):609-18
references.pmid: 15659508
references.citation: Am J Pathol. 1998 Oct;153(4):1063-78
references.pmid: 9777938
references.citation: Int J Cancer. 2001 Jul 1;93(1):6-11
references.pmid: 11391614
references.citation: Clin Colorectal Cancer. 2007 Nov;6(10):683-90
references.pmid: 18039421
references.citation: Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77
references.pmid: 17014575
references.citation: J Clin Lab Anal. 2006;20(2):52-61
references.pmid: 16538640
references.citation: World J Surg Oncol. 2005 May 12;3:26
references.pmid: 15890075
references.citation: Oncology. 2003;64(3):259-65
references.pmid: 12697967
references.citation: Br J Cancer. 2005 May 9;92(9):1746-53
references.pmid: 15856045
references.citation: Hum Pathol. 1999 Jun;30(6):629-34
references.pmid: 10374769
references.citation: JAMA. 1990 Sep 19;264(11):1444-50
references.pmid: 2202842
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Oncol Rep. 2005 Jul;14(1):241-9
references.pmid: 15944796
references.citation: Int J Cancer. 2006 Jan 1;118(1):6-10
references.pmid: 16003753
references.citation: Lancet. 2005 Jan 8-14;365(9454):153-65
references.pmid: 15639298
references.citation: Eur J Cancer. 2009 Aug;45(12):2138-45
references.pmid: 19409772
references.citation: Br J Surg. 2004 Apr;91(4):469-75
references.pmid: 15048750
references.citation: Hum Pathol. 2004 Jul;35(7):808-16
references.pmid: 15257543
references.citation: Gastroenterology. 2008 Apr;134(4):988-97
references.pmid: 18395080
references.citation: Am J Pathol. 2001 Jul;159(1):297-304
references.pmid: 11438476
references.citation: Cancer Res. 2003 Sep 1;63(17):5564-72
references.pmid: 14500396
references.citation: Cancer Immunol Immunother. 2008 May;57(5):601-9
references.pmid: 17874100
references.citation: Crit Rev Immunol. 1995;15(3-4):359-84
references.pmid: 8834456
references.citation: Cancer Res. 2009 Mar 15;69(6):2685-93
references.pmid: 19258510
references.citation: J Pathol. 1997 Jul;182(3):318-24
references.pmid: 9349235
references.citation: Br J Cancer. 1999 Sep;81(2):190-3
references.pmid: 10496341
references.citation: Br J Cancer. 2005 Feb 28;92(4):651-4
references.pmid: 15700032
references.citation: Gut. 2000 Feb;46(2):200-4
references.pmid: 10644313
references.citation: J Pathol. 1999 Dec;189(4):487-95
references.pmid: 10629548
references.citation: Eur J Cancer. 2008 Oct;44(15):2288-95
references.pmid: 18707864
references.citation: Cancer Res. 2007 Mar 1;67(5):1883-6
references.pmid: 17332313
references.citation: Jpn J Clin Oncol. 2004 Feb;34(2):90-8
references.pmid: 15067103
references.citation: Cancer Immunol Immunother. 2003 Jul;52(7):423-8
references.pmid: 12695859
references.citation: Eur J Cancer. 2005 Nov;41(17):2645-54
references.pmid: 16239109
references.citation: Fam Cancer. 2009;8(3):231-9
references.pmid: 19165625
references.citation: J Pathol. 1999 May;188(1):14-7
references.pmid: 10398134
references.citation: Lab Invest. 2004 Apr;84(4):493-501
references.pmid: 14968119
references.citation: N Engl J Med. 2005 Dec 22;353(25):2654-66
references.pmid: 16371631
references.citation: Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3
references.pmid: 17122624
references.citation: J Mol Diagn. 2008 Mar;10(2):154-9
references.pmid: 18258928
references.citation: Ann Surg. 2009 May;249(5):788-93
references.pmid: 19387324
references.citation: Cancer Res. 1998 Aug 15;58(16):3491-4
references.pmid: 9721846
references.citation: Gut. 2001 Mar;48(3):360-6
references.pmid: 11171826
references.citation: Eur J Cancer. 2007 Jun;43(9):1348-60
references.pmid: 17512720
references.citation: Ann Oncol. 2004 Feb;15(2):242-6
references.pmid: 14760116
references.citation: Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57
references.pmid: 12672517
references.citation: Br J Cancer. 2004 Jun 1;90(11):2053-8
references.pmid: 15164120
references.citation: Cancer Immun. 2009 Feb 19;9:1
references.pmid: 19226101
references.citation: Cancer Biother Radiopharm. 2009 Jun;24(3):369-76
references.pmid: 19538060
references.citation: N Engl J Med. 2005 Dec 22;353(25):2640-1
references.pmid: 16371629
references.citation: Lancet. 1987 Jun 6;1(8545):1303-6
references.pmid: 2884421
references.citation: Oncol Rep. 2003 Mar-Apr;10(2):309-13
references.pmid: 12579264
references.citation: Semin Oncol. 1995 Dec;22(6):600-10
references.pmid: 8539635